Current Research:
Retatrutide is an innovative weight loss agent that acts as a triple receptor agonist, targeting GLP-1, GIP, and glucagon receptors. This triple action is designed to provide enhanced metabolic benefits by combining the effects of GLP-1 and GIP with glucagon, which can promote fat oxidation and energy expenditure. Retatrutide’s unique mechanism of action sets it apart from other weight loss medications, potentially offering superior weight reduction and metabolic improvements.

For Research only! You must be 21 or older.